A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

NCT05272813 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped The study is terminated due to major protocol revisions.

Conditions

Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: MS-553

Sponsor

Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.